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Michael J. Rinaldi, MD,f Franz-Josef Neumann, MD,g D. Christopher Metzger, MD,h Timothy D. Henry, MD,i,j
David A. Cox, MD,k Peter L. Duffy, MD, MMM,l Ernest L. Mazzaferri, JR, MD,m Roxana Mehran, MD,b,n
Rupa Parvataneni, MS,b Bruce R. Brodie, MD,d Gregg W. Stone, MDb,c

ABSTRACT
OBJECTIVES The aim of this study was to understand the impact of the timing of ischemic and hemorrhagic events
after percutaneous coronary intervention (PCI) with drug-eluting stents on subsequent mortality.
BACKGROUND These events have been strongly associated with subsequent death.
METHODS In the multicenter, prospective ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug Eluting
Stents) study, patients at 11 clinical sites with successful PCI with drug-eluting stents underwent assessment of platelet
function and were followed for 2 years. Events occurring after PCI—deﬁnite or probable stent thrombosis (ST), myocardial
infarction (MI) not related to ST, and clinically relevant bleeding (CB)—were classiﬁed as early (#30 days), late (31 to
365 days), or very late (>365 days). Mortality within 30 days of each event was estimated by Kaplan-Meier methodology.
Cox regression multivariate modeling was used to analyze the relationship between each event (as a time-updated
variable) and mortality over the entire study period.
RESULTS Among 8,582 patients, 1,060 (12.4%) had events—691 (8.1%) had CB, 294 (3.4%) had MI, and 75 (0.9%) had
ST—and 7,522 (87.6%) had no events. The highest risk was associated with early ST (38.5% mortality at 30 days after the
event), whereas very late MI (7.5%) and late CB (7.3%) were less dangerous. By multivariate analysis, each event was
independently predictive of death, with hazard ratios of 2.4, 1.8, and 11.4, respectively (p < 0.0001).
CONCLUSIONS Approximately 1 in 8 patients successfully undergoing PCI with drug-eluting stents had CB, MI, or ST
during the ensuing 2 years. These events are associated with an increased hazard of mortality, particularly within the ﬁrst
30 days following the event, warranting efforts to prevent their occurrence. (J Am Coll Cardiol Intv 2016;9:1450–7)
© 2016 by the American College of Cardiology Foundation.
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Ischemic and Hemorrhagic Events After DES
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T A B L E 1 Baseline and Procedural Characteristics of Patients With and Without Events

Age, yrs

MI
(n ¼ 294)

ST
(n ¼ 75)

CB
(n ¼ 691)

No MI, ST, or CB
(n ¼ 7,522)

p Value

64.6  11.2 (294)

62.1  12.0 (75)

66.9  10.5 (691)

63.3  10.8 (7,522)

<0.0001
0.10

Male

73.8% (217/294)

72.0% (54/75)

68.9% (476/691)

74.6% (5,610/7,522)

Diabetes

44.2% (130/294)

48.0% (36/75)

33.7% (233/691)

31.7% (2,384/7,522) <0.0001

22.4% (66/294)

20.0% (15/75)

13.3% (92/691)

11.0% (825/7,522)

<0.0001

History of peripheral arterial disease

19.0% (56/294)

18.7% (14/75)

14.3% (99/691)

9.4% (707/7,522)

<0.0001

History of congestive heart failure

13.9% (41/294)

5.3% (4/75)

12.3% (85/691)

7.6% (569/7,522)

<0.0001

Previous MI

33.7% (99/294)

38.7% (29/75)

26.2% (181/691)

24.7% (1,855/7,522)

Previous CABG

28.9% (85/294)

20.0% (15/75)

18.2% (126/691)

16.5% (1,242/7,522) <0.0001

Previous PCI

50.7% (149/294)

53.3% (40/75)

46.3% (320/691)

42.1% (3,169/7,522)

0.001

3.1% (9/294)

5.3% (4/75)

3.0% (21/691)

1.4% (104/7,522)

<0.0001

Hypertension

84.7% (249/294)

86.7% (65/75)

86.0% (594/691)

Hyperlipidemia

79.9% (235/294)

74.7% (56/75)

79.6% (550/691)

73.6% (5,539/7,522)

0.0008

Cigarette smoking

55.4% (163/294)

68.0% (51/75)

54.1% (374/691)

56.4% (4,241/7,522)

0.13
0.08

Insulin treated

History of dialysis

Current (within 1 month)

0.0002

78.8% (5,925/7,522) <0.0001

21.4% (63/294)

32.0% (24/75)

20.0% (138/691)

22.8% (1,715/7,522)

59.5% (175/294)

64.0% (48/75)

42.7% (295/691)

52.0% (3,915/7,522) <0.0001

Unstable angina

31.6% (93/294)

28.0% (21/75)

22.7% (157/691)

27.9% (2,099/7,522)

Non–ST-segment elevation

23.1% (68/294)

17.3% (13/75)

14.2% (98/691)

14.2% (1,070/7,522)

ST-segment elevation

4.8% (14/294)

18.7% (14/75)

5.8% (40/691)

9.9% (746/7,522)

<0.0001

2.1% (155/7,522)

0.38

Acute coronary syndrome

Killip class II–IV at time of PCI

0.02
0.0003

2.7% (8/294)

0.0% (0/75)

2.6% (18/691)

Anemia

29.3% (86/294)

25.3% (19/75)

29.4% (203/691)

20.9% (1,564/7,486) <0.0001

Creatinine clearance <60 ml/min

24.0% (70/292)

20.0% (15/75)

25.9% (179/690)

15.2% (1,138/7,486) <0.0001
39.7% (2,984/7,522) <0.0001

Degree of coronary artery disease
1 vessel

21.8% (64/294)

32.0% (24/75)

30.5% (211/691)

2 vessels

36.4% (107/294)

36.0% (27/75)

32.9% (227/691)

32.9% (2,474/7,522)

3 vessels

41.8% (123/294)

32.0% (24/75)

36.6% (253/691)

27.4% (2,064/7,522) <0.0001

Left main >50% stenosis
Ejection fraction <40%
Radial access

3.7% (11/294)

2.7% (2/75)

5.2% (36/691)

35.7% (105/294)

38.7% (29/75)

46.0% (318/691)

2.8% (208/7,522)

0.60
0.004

28.2% (2,124/7,522) <0.0001

7.1% (21/294)

6.7% (5/75)

2.5% (17/691)

4.4% (332/7,522)

0.06

1.29  0.54 (294)

1.16  0.40 (75)

1.26  0.52 (691)

1.17  0.41 (7,522)

<0.0001

Lesions treated per patient

1.69  1.01 (294)

1.47  0.78 (75)

1.60  0.86 (691)

1.49  0.77 (7,522)

<0.0001

Stents implanted per patient

2.02  1.32 (294)

1.84  1.21 (75)

1.92  1.14 (691)

1.69  0.99 (7,522) <0.0001

Vessels treated per patient

XIENCE/Promus
Total stent length, mm
Any GPI during index PCI
Time to VerifyNow from PCI, h
ARU
$550 ARU
PRU
>208 PRU

67.7% (199/294)

49.3% (37/75)

59.2% (409/691)

65.0% (4,893/7,522)

39.5  28.2 (294)

36.4  25.6 (75)

36.4  25.0 (691)

31.8  21.7 (7,522)

<0.0001

0.0004

4.1% (12/294)

10.7% (8/75)

3.6% (25/691)

3.1% (231/7,522)

0.002

19.11 (16.50–22.40) 18.58 (15.58–23.30) 19.73 (17.10–22.38) 18.90 (16.20–21.67) <0.0001
400 (390–433)

404 (390–426)

399 (387–426)

401 (388–424)

5.2% (15/291)

5.3% (4/75)

5.2% (36/686)

5.7% (423/7,474)

0.48
0.95

215 (125–285)

233 (158–299)

173 (92–250)

187.50 (115–260)

<0.0001

42.5% (3,150/7,412) <0.0001

52.4% (151/288)

61.3% (46/75)

38.9% (262/673)

Both $550 ARU and >208 PRU

1.8% (5/285)

5.3% (4/75)

2.4% (16/668)

2.5% (188/7,373)

0.37

No aspirin at discharge

0.3% (1/292)

1.4% (1/73)

1.0% (7/689)

0.8% (59/7,522)

0.68

78.6% (231/294)

77.3% (58/75)

60.6% (419/691)

Daily aspirin without discontinuation for 2 yrs
No clopidogrel at discharge

82.4% (6,200/7,522) <0.0001

0.3% (1/292)

0.0% (0/73)

1.2% (8/689)

Daily clopidogrel without discontinuation for 1 yr

70.4% (207/294)

65.3% (49/75)

55.0% (380/691)

77.8% (5,854/7,522) <0.0001

0.2% (17/7,522)

0.0003

Daily clopidogrel without discontinuation for 2 yrs

50.7% (149/294)

44.0% (33/75)

25.9% (179/691)

51.2% (3,855/7,522) <0.0001

Values are mean  SD (N), % (n/N), or median (interquartile range). Patients were analyzed according to ﬁrst event.
ARU ¼ aspirin reaction units; CABG ¼ coronary artery bypass grafting; CB ¼ clinically relevant bleeding; GPI ¼ glycoprotein IIb/IIIa receptor inhibitor; MI ¼ myocardial
infarction; PCI ¼ percutaneous coronary intervention; PRU ¼ P2Y12 reaction units; ST ¼ stent thrombosis.
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hospital discharge and were periprocedural MI), and

tween the groups, with more risk factors for coronary

75 (0.9%) had ST (8 of which occurred before hospital

artery disease present in patients with events,

discharge)—and 7,522 (87.6%) had no events. Key

particularly in those with MI or ST. Signiﬁcantly

baseline and procedural characteristics of the 4

more stents were implanted in patients with subse-

groups are shown in Table 1. There were multiple and
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events

than
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without
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T A B L E 2 Adjudicated Ischemic Clinical Events Up to 2 Years

MI
(n ¼ 294)

ST
(n ¼ 75)

CB
(n ¼ 691)

No MI, ST, or CB
(n ¼ 7,522)

p Value

All events
Cardiac death/MI/deﬁnite/probable ST

100% (294)

100% (75)

1.42% (100)

<0.0001

Death/MI/ischemic TVR

100% (294)

98.67% (74)

27.33% (186)

10.05% (718)

<0.0001

Death/MI

100% (294)

91.76% (68)

15.36% (104)

2.66% (190)

<0.0001

Cardiac death/MI

100% (294)

91.76% (68)

9.30% (61)

1.42% (100)

<0.0001

12.43% (35)

27.15% (20)

10.54% (71)

2.66% (190)

<0.0001

9.61% (27)

27.15% (20)

5.85% (38)

1.58% (112)

<0.0001

Death
Cardiovascular
Noncardiovascular
MI
ST-related MI

9.44% (62)

1.10% (78)

<0.0001

3.12% (8)

0.00% (0)

4.99% (33)

100.00% (294)

90.14% (59)

5.89% (38)

0.00% (0)

<0.0001

0.00% (0)

0.00% (0)

<0.0001

2.17% (6)

86.97% (57)

Non–ST-related MI

63.05% (179)

0.00% (0)

3.83% (24)

0.00% (0)

<0.0001

Periprocedural MI

38.21% (112)

2.67% (2)

2.06% (14)

0.00% (0)

<0.0001

0.29% (2)

0.00% (0)

<0.0001

Deﬁnite/probable ST

5.68% (16)

100.00% (75)

Early (30 days)
Cardiac death/MI/deﬁnite/probable ST

38.44% (113)

48.00% (36)

1.88% (13)

0.00% (0)

<0.0001

Death/MI/ischemic TVR

39.12% (115)

48.00% (36)

2.90% (20)

0.32% (24)

<0.0001

Death/MI

38.44% (113)

46.67% (35)

2.17% (15)

0.03% (2)

<0.0001

Cardiac death/MI

38.44% (113)

46.67% (35)

1.74% (12)

0.00% (0)

<0.0001

0.34% (1)

16.00% (12)

0.58% (4)

0.03% (2)

<0.0001

0.34% (1)

16.00% (12)

0.29% (2)

0.01% (1)

<0.0001

0.29% (2)

Death
Cardiovascular
Noncardiovascular
MI

0.00% (0)

0.00% (0)

38.44% (113)

36.17% (26)

1.74% (12)

0.01% (1)

0.19

0.00% (0)

<0.0001

0.34% (1)

33.45% (24)

0.00% (0)

0.00% (0)

<0.0001

Non–ST-related MI

1.72% (5)

0.00% (0)

0.15% (1)

0.00% (0)

<0.0001

Periprocedural MI

36.39% (107)

2.67% (2)

1.59% (11)

0.00% (0)

<0.0001

48.00% (36)

0.29% (2)

0.00% (0)

<0.0001

ST-related MI

Deﬁnite/probable ST

0.34% (1)

Late (>30 days to 1 yr)
Cardiac death/MI/deﬁnite/probable ST

34.47% (100)

43.53% (27)

4.16% (28)

0.59% (43)

<0.0001

Death/MI/ischemic TVR

39.98% (116)

45.15% (28)

15.96% (109)

5.69% (417)

<0.0001

Death/MI

34.12% (99)

34.25% (21)

7.18% (49)

1.23% (90)

<0.0001

Cardiac death/MI

34.12% (99)

34.25% (21)

4.16% (28)

0.59% (43)

<0.0001
<0.0001

Death

5.86% (17)

4.87% (3)

5.42% (37)

1.23% (90)

Cardiovascular

5.18% (15)

4.87% (3)

2.81% (19)

0.68% (50)

<0.0001

Noncardiovascular

0.71% (2)

0.00% (0)

2.68% (18)

0.55% (40)

<0.0001

33.55% (97)

32.02% (19)

1.95% (13)

0.00% (0)

<0.0001

ST-related MI

0.70% (2)

28.65% (17)

0.00% (0)

0.00% (0)

<0.0001

Non–ST-related MI

31.97% (92)

0.00% (0)

1.81% (12)

0.00% (0)

<0.0001

Periprocedural MI

1.06% (3)

0.00% (0)

0.15% (1)

0.00% (0)

<0.0001

3.48% (10)

39.95% (24)

0.00% (0)

0.00% (0)

<0.0001
<0.0001

MI

Deﬁnite/probable ST
Very late (>1 to 2 yrs)
Cardiac death/MI/deﬁnite/probable ST

37.34% (99)

33.31% (19)

3.81% (23)

0.83% (57)

Death/MI/ischemic TVR

42.91% (114)

38.58% (22)

11.65% (73)

4.90% (332)

<0.0001

Death/MI

38.31% (102)

33.31% (19)

6.90% (43)

1.43% (98)

<0.0001

Cardiac death/MI

37.34% (99)

33.31% (19)

3.81% (23)

0.83% (57)

<0.0001

6.66% (17)

8.84% (5)

4.86% (30)

1.43% (98)

<0.0001

Death
Cardiovascular

4.34% (11)

8.84% (5)

2.84% (17)

0.89% (61)

<0.0001

Noncardiovascular

2.43% (6)

0.00% (0)

2.08% (13)

0.54% (37)

<0.0001

36.86% (97)

32.01% (18)

2.53% (15)

0.00% (0)

<0.0001

1.14% (3)

28.45% (16)

0.00% (0)

0.00% (0)

<0.0001

Non–ST-related MI

31.38% (82)

0.00% (0)

1.88% (11)

0.00% (0)

<0.0001

Periprocedural MI

0.75% (2)

0.00% (0)

0.33% (2)

0.00% (0)

<0.0001

1.89% (5)

30.22% (17)

0.00% (0)

0.00% (0)

<0.0001

MI
ST-related MI

Deﬁnite/probable ST

Values are 2-year Kaplan-Meier event rate (number of events). Percentages refer to the proportion of patients with each adverse event.
TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
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F I G U R E 1 Time to Death (Within 30 Days or to Study End) After a

Non–Stent Thrombosis–Related Myocardial Infarction, According to Timing of
Myocardial Infarction Relative to Index Percutaneous Coronary Intervention
(Unadjusted Hazard Ratios)

Uninterrupted dual-antiplatelet therapy, as expected,
was substantially less common among patients with
CB at 1 and 2 years.
Adjudicated ischemic clinical events up to 2 years
are shown in Table 2. All-cause (and cardiovascular)
death was signiﬁcantly more common in patients
with ST than in any other group (27.2%), whereas
those without any events had the lowest mortality
rate (2.7%) (p < 0.0001). It is notable that the incidence of deﬁnite or probable ST after CB was only
0.29%, and there was no MI in this cohort.
Figures 1 to 3 depict time to death in the 30 days after
MI, ST, or CB, according to the timing of each event
relative to index PCI (unadjusted hazard ratios [HRs]).
The graphs depict the total number of each type of
event, including additional events in patients with
multiple events. As such, in total, there were 316 MIs
not related to ST, 92 deﬁnite or probable ST events,
and 739 CB events. There were very few (1 CB and 5 MI)
events in the last 30 days of the study, and these
patients had thus incomplete 30-day follow-up

The cumulative rates of death within 30 days of a non–stent thrombosis (ST)–related

beyond the occurrence of these events. For MI, the

myocardial infarction (MI), in patients who had MI occur within 30 days of percutaneous

very late events were associated with the highest

coronary intervention (PCI) (black line), 30 to 365 days after PCI (green line), and more

death rate at 30 days: a 10-fold increase compared with

than 1 year after PCI (blue line) are shown with respective hazard ratios (HRs) compared

early MI and an absolute rate of 7.5%. In contrast, early

with the reference of MI within 30 days of PCI.

ST carried the highest risk in this category, with an
absolute rate of death of 38.5%, whereas later ST was
associated with roughly one-half to one-third of that

F I G U R E 2 Time to Death (Within 30 Days or to Study End) After Deﬁnite or

mortality rate. CB was associated with mortality rates

Probable Stent Thrombosis, According to Timing of Stent Thrombosis Relative to

similar to MI, with the lowest observed for early

Index Percutaneous Coronary Intervention (Unadjusted Hazard Ratios)

bleeding. It is notable that for patients with CB, onehalf of the mortality, roughly, was noncardiovascular.
The signiﬁcant predictors of 2-year death by stepwise multivariate modeling, including events after
PCI as time-updated variables, are shown in Table 3.
The highest risk was conferred by ST, whereas
bleeding and MI (not related to ST) had smaller but
similar contributions to risk for death. Notably, presentation with MI (vs. stable or unstable angina),
non– insulin-treated diabetes mellitus (vs. no diabetes), and HPR were not independent predictors of
death.

DISCUSSION
The principal ﬁndings of this study can be summarized as follows: 1) the risk for death is increased by
post-PCI ischemic and hemorrhagic events; 2) early
ST and very late spontaneous MI carry the highest risk
The cumulative rates of death within 30 days of deﬁnite or probable stent thrombosis (ST),
in patients who had ST occur within 30 days of percutaneous coronary intervention (PCI)
(black line), 30 to 365 days after PCI (green line), and more than 1 year after PCI (blue

for subsequent short-term death, whereas early
bleeding appears least dangerous; and 3) bleeding

line) are shown with respective hazard ratios (HRs) compared with the reference of ST

and non– ST-related MI increase the risk for death to a

within 30 days of PCI.

similar and lower extent than ST. Early MIs portended
a low risk for death, as many of these events were
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periprocedural events, which appear to lack prognostic signiﬁcance (8).

F I G U R E 3 Time to Death (Within 30 Days or to study End) After Clinically

Relevant Bleeding, According to Timing of Clinically Relevant Bleeding Relative to

Ndrepepa et al. (9) culled 5,384 patients from

Index Percutaneous Coronary Intervention (Unadjusted Hazard Ratios)

4 studies of PCI with glycoprotein IIb/IIIa receptor inhibitor or placebo and showed that bleeding (all
events, TIMI criteria) within 30 days after PCI was an
independent predictor of 1-year mortality (HR: 2.96;
95% conﬁdence interval [CI]: 1.96 to 4.48; p < 0.001),
similar to the effect of early MI (HR: 2.29; 95% CI: 1.52
to 3.46; p < 0.001). Their report included only early
events, but the HRs were similar to those found in this
analysis of a larger population followed for a longer
duration including stricter deﬁnitions for signiﬁcant
bleeding and separating MI from episodes of ST.
Stone et al. (10) evaluated the relative impact of
major bleeding and reinfarction on 3-year cardiac
mortality in 3,602 patients with ST-segment elevation
MI enrolled in the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute
Myocardial

Infarction).

They

found

that

major

bleeding (HR: 2.53; 95% CI: 1.61 to 3.98; p < 0.001) and
reinfarction (HR: 7.88; 95% CI: 4.62 to 13.42; p < 0.001)
carried signiﬁcant prognostic information. Our data

The cumulative rates of death within 30 days of a clinically relevant bleeding (CB) event,
in patients who had CB occur within 30 days of percutaneous coronary intervention
(PCI) (black line), 30 to 365 days after PCI (green line), and more than 1 year after PCI

extend these observations in a more diverse cohort of

(blue line) are shown with respective hazard ratios (HRs) compared with the reference of

patients and add granularity to the information by

CB within 30 days of PCI.

including ST and analyzing the different intervals from
PCI to the ischemic or hemorrhagic event.
Pocock et al. (11) performed an analysis of the
effects of CB or MI in the ﬁrst 30 days after acute

mortality was not related to ST or MI resulting from the
possible interruption of antithrombotic therapy. In
this respect, our data reinforce the possibility that CB is

coronary syndromes on 1-year mortality in the

a marker of comorbidity and not necessarily a direct

ACUITY study. In a time-updated Cox regression

cause of death, as one-half the mortality was non-

model, each of these complications signiﬁcantly

cardiovascular, closely resembling the distribution of

increased mortality (HR: 2.93; 95% CI: 2.29 to 3.74;

death causes among patients without any adverse

p < 0.001; and HR: 2.66; 95% CI: 2.06 to 3.43;
p < 0.001, respectively). Of the 77 deaths occurring
after MI, two-thirds happened within 30 days of MI,

events.
T A B L E 3 Signiﬁcant Predictors of Death at 2 Years

and the rest occurred within 1 year. In another analysis from ACUITY, the risk for death after MI was

Hazard Ratio

95% Conﬁdence
Interval
p Value

particularly high early on, whereas the contribution

Age, yrs

1.05

1.03–1.06

of bleeding to death was more constant over 1 year of

Male

1.36

1.04–1.78

0.02

follow-up (12). Our data, again, extend these obser-

Insulin-requiring diabetes mellitus

1.78

1.32–2.40

0.0001

vations to patients without acute coronary syn-

Previous MI (>7 days before percutaneous
coronary intervention)

1.37

1.08–1.73

0.01

dromes also and included events occurring at any
point in the ADAPT-DES trial, not just in the ﬁrst

<0.0001

Chronic kidney disease

1.44

1.05–1.99

0.02

Creatinine clearance

0.99

0.99–1.00

0.04

30 days after hospitalization. Moreover, we separated

Cigarette smoking

1.37

1.08–1.73

0.01

the impact of spontaneous MI from that of ST.

Baseline hemoglobin

0.82

0.75–0.89

<0.0001

Genereux et al. (13) evaluated the signiﬁcance

Baseline white blood cell count

1.10

1.06–1.14

<0.0001

Clinically relevant bleeding

2.43

1.86–3.18

<0.0001

(two-thirds of all the bleeding events) and showed

Stent thrombosis

11.37

7.61–16.98

<0.0001

that after multivariate adjustment, it was associated

MI without stent thrombosis

of post–hospital discharge bleeding in ADAPT-DES

with signiﬁcantly higher 2-year mortality (HR: 5.03;
p < 0.0001), with an effect size greater than that of
post-discharge MI. The present analysis adds granu-

1.84

1.24–2.72

0.002

Other variables considered (but not found signiﬁcant): MI versus stable or unstable angina at
presentation, non– insulin-dependent diabetes, arterial hypertension, hyperlipidemia, high
platelet reactivity, and multivessel coronary artery disease.
MI ¼ myocardial infarction.

larity to these data and shows that the increased
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Why early ST is more likely to result in death than

over a 2-year period. When these events occur, they

later ST remains unclear, although similar observa-

substantially increase risk for death, particularly if

tions were made in the setting of PCI for acute ST-

early ST or very late spontaneous MI is considered.

segment elevation MI (14) and elective PCI (15,16).

These data provide additional impetus to further

Our data also echo the large analysis from the

attempt to eliminate early ST by improving PCI

National Cardiovascular Data Registry CathPCI regis-

techniques and using adequate antithrombotic ther-

try, which showed that among 7,315 cases of ST, the

apy and prevent the progression of coronary artery

ones occurring early (with the same temporal deﬁni-

disease and plaque rupture with aggressive risk factor

tions as in our study) were associated with 2-fold

modiﬁcation.

higher in-hospital mortality compared with those
occurring late or very late (7.8% vs. 3.8% vs. 3.6%,
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respectively, p < 0.001) (17). It is possible that earlier
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events occur more abruptly, without previous reste-

Catheterization Laboratory, 506 6th Street, KP-2,

nosis leading to the formation of collateral channels.
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STUDY STRENGTHS AND LIMITATIONS. The main

strengths of the present analysis are the inclusion of all

PERSPECTIVES

events, not just the early ones; their categorization
according to interval from PCI; and the more extended

WHAT IS KNOWN? Ischemic or bleeding events

follow-up in a diverse population. That being said,

after PCI adversely affect prognosis. Less well deﬁned

we also recognize important limitations. Signiﬁcant

is the impact of timing of these events relative to PCI

bleeding in this analysis was on the basis of site

on prognosis.

reporting, without independent adjudication, and
included a rather broad range of events, albeit in tune
with the recent efforts to standardize bleeding deﬁnitions (18). ADAPT-DES included a population of patients who underwent successful PCI with DES and thus
may not represent the entire universe of PCI patients.

WHAT IS NEW? This study conﬁrms the negative
impact of these complications on prognosis and
identiﬁes ST occurring within the ﬁrst 30 days after
PCI as the event with the highest subsequent mortality, followed by late spontaneous MI.
WHAT IS NEXT? Additional studies are needed to

CONCLUSIONS

conﬁrm the improved outcomes resulting from pre-

Despite these limitations, we conclude that 1 in every
8 patients treated with initially successful PCI with

vention of both early ST and late spontaneous MI in
patients with prior PCI.

DES had an episode of ST or MI not related to ST or CB
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